Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma

LESSONS LEARNED. Combination regimen with bevacizumab (BEV) and vorinostat is well tolerated in patients with recurrent glioblastoma. Treatment of recurrent glioblastoma remains challenging as this study and others attempt to improve progression‐free survival and overall survival with BEV‐containing...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghiaseddin, Ashley, Reardon, David, Massey, Woody, Mannerino, Alex, Lipp, Eric S., Herndon, James E., McSherry, Frances, Desjardins, Annick, Randazzo, Dina, Friedman, Henry S., Peters, Katherine B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813746/
https://www.ncbi.nlm.nih.gov/pubmed/29133513
http://dx.doi.org/10.1634/theoncologist.2017-0501

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813746/
https://www.ncbi.nlm.nih.gov/pubmed/29133513
http://dx.doi.org/10.1634/theoncologist.2017-0501

Ejemplares similares